Henrietta biopharmaceutical company OyaGen Inc. has received $150,000 in investment funding from the New York State Common Retirement Fund, Comptroller Thomas DiNapoli announced Monday.
The funding, through Perinton-based Trillium Group LLC, increases the fund’s investment total in OyaGen to nearly $1.4 million since 2006. DiNapoli made the announcement during a visit to the company.
“OyaGen is doing groundbreaking research right here in New York State, and the pension fund is committed to helping ensure this company’s success,” DiNapoli said.
The investment is part of the retirement fund’s In-State Private Equity Program, which partners with Trillium and 17 other private-equity firms investing in New York-based companies.
The in-state program has made 20 investments totaling $81.2 million in Monroe, Genesee, Ontario, Wyoming and Yates counties, DiNapoli said.
More than $1 billion has been committed to the in-state program, with $684 million invested in 252 New York companies, he said. Some $393 million remains available.
OyaGen, formed in 2003, is researching, developing and commercializing pharmaceutical therapies that seek to exploit a new genetic approach to disease control.
The company is working to develop a functional cure for HIV/AIDS.
(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email email@example.com.